Bifidobacterium longum
Bifidobacterium longum is a probiotic gut bacterium; bifidobacteria often dominate the gut of breastfed infants and make up a much smaller share of the adult gut. Its effects depend on the strain: each trial on this page tested one named strain, and strains 1714, BB536, 35624 and R0175 have their own pages on this site. Strain 1714 did not beat placebo on the main sleep, stress or mood scores of its randomized trials, though some secondary sleep and mood ratings did. Strain 35624, formerly named subspecies infantis, was assigned to subspecies longum by genome analysis; it eased abdominal discomfort at one of three doses in one trial, a result that does not pass a correction for three doses, and pooled analyses disagree. BB536 was tested for bowel regularity, nasal comfort in pollen season and respiratory illnesses. Most trials were funded, supplied or co-authored by the companies behind the strains.
Benefits
Bowel regularity in older adults (BB536 strain)
In 80 older adults (mean age 78) with chronic constipation, 50 billion CFU a day of BB536 for 4 weeks did not beat placebo on the main constipation score (P = 0.074), but stool frequency, a secondary measure, improved more than on placebo. In 60 young male athletes, BB536 for 4 weeks did not differ from placebo on digestive symptoms. Morinaga staff co-authored both trials; see the BB536 page.
Abdominal comfort and bloating (35624 strain)
In a 4-week trial in 362 women with IBS, capsules of strain 35624 at 100 million CFU eased abdominal pain, bloating and other bowel symptoms more than placebo, but the 1 million and 10 billion doses did not; recalculated in a later pooled analysis, the pain result had P = 0.020, which does not pass a correction for three doses, and two pooled analyses disagree. A trial of 1 billion CFU a day in adults who had not seen a doctor found no difference from placebo in symptom severity. See the strain 35624 page.
Upper respiratory immune support in children and older adults (BB536 strain)
Tested as the BB536 strain only. In 520 Malaysian preschoolers given 5 billion CFU a day or placebo for 10 months, the BB536 group had fewer respiratory illnesses and 46% shorter sore throats, but only the 219 fully compliant children were analyzed, and diarrhea did not change. In 27 older adults, fewer caught influenza or had fever than on placebo over 14 weeks. Morinaga, which makes BB536, co-authored both; see the BB536 page.
Nasal comfort scores in a seasonal trial (BB536 strain)
In 44 people with Japanese cedar pollen allergy, BB536 taken for 13 weeks of the pollen season led to fewer early dropouts for severe symptoms or medication and lower runny nose, blocked nose and overall symptom scores than placebo. This is one small trial whose first author was from Morinaga, the strain's maker.
Sleep quality ratings (1714 strain)
Tested as the 1714 strain at 1 billion CFU a day. In 89 adults with poor sleep, the main sleep score improved similarly on the strain and placebo over 8 weeks, but rated sleep quality and daytime sleepiness improved faster by week 4; a wrist monitor showed no difference. In a randomized crossover study in 20 students, sleep quality and duration during exams were better than on placebo, though the main stress goal was not met.
Mood and vitality in adults with low mood (1714 strain)
Tested as the 1714 strain at 10 billion CFU a day. In 168 adults with mild to moderate depression who took no antidepressants, the main depression score did not differ from placebo at 4 or 8 weeks. A second depression questionnaire and mental health, vitality and social role ratings were better at week 4, and vitality stayed better at week 8. The maker sponsored the trial.
Stress response in healthy adults (1714 strain)
In 22 healthy men who took placebo for 4 weeks and then the 1714 strain for 4 weeks, in a fixed, non-randomized order, total cortisol output in a cold-water stress test and daily stress ratings were lower after the strain. In randomized trials, felt stress did not differ from placebo in 20 students during exams or in 40 adults after a social stress game.
Mechanism of action
Gut-brain signaling (proposed)
How strain 1714 might affect the brain is not settled. Researchers propose that gut microbes signal to the brain through neural, hormonal and immune pathways. Changes in EEG and MEG brain activity in 1714 trials suggest some effect on the brain, but the pathway has not been shown in people.
Human milk oligosaccharide use
The infantis subspecies carries a large gene cluster for breaking down human milk oligosaccharides, sugars in breast milk that the infant cannot digest. This helps explain why it thrives in the gut of breastfed babies.
Cross-feeding of butyrate producers
Bifidobacteria ferment fibers and other carbohydrates the body cannot digest. Their products, such as acetate and lactate, can be used by other colon bacteria that make butyrate, the main fuel for the cells lining the colon.
Clinical trials
Randomized, double-blind, placebo-controlled multicenter trial of encapsulated B. infantis 35624 (now classified as B. longum 35624) at 1 million, 100 million or 10 billion CFU for 4 weeks; the abstract gives the units as cfu/mL. The matching registry entry, NCT00135031, lists Procter & Gamble as lead sponsor and Alimentary Health Ltd as collaborator. (Whorwell et al. 2006, Am J Gastroenterol)
362 women with IBS of any bowel habit subtype, recruited from primary care, randomized to one of three doses or placebo for 4 weeks.
Only the 100 million (1 x 10^8) dose beat placebo and the other doses on abdominal pain (the primary outcome), the composite score, bloating, bowel dysfunction, incomplete evacuation, straining and passage of gas; global symptom relief exceeded placebo by more than 20%. The 1 million and 10 billion doses did not differ from placebo, and the 10 billion dose had formulation problems. No significant adverse events were recorded. Recalculated in a 2026 pooled analysis, the 100 million arm had P = 0.020 against placebo for abdominal pain, above the cutoff of about 0.017 for three doses.
Ten-center, double-blind, randomized, placebo-controlled parallel trial: 2-week placebo run-in, then 4 weeks of 1 billion CFU a day or placebo. One author was from Procter & Gamble. (Ringel-Kulka et al. 2017, Am J Gastroenterol)
302 adults recruited by advertisement with abdominal discomfort and bloating at least twice a week for 3 months or more, who had not seen a doctor or taken prescribed medication for it in the past year; 275 gave evaluable data.
End-of-study severity of abdominal discomfort and bloating did not differ from placebo (P > 0.3), with both groups improving. The frequency of bloating-free days, also assessed, was greater on the strain (P < 0.05).
Randomized, double-blind, placebo-controlled parallel-group trial (UMIN 000033031) of BB536 (50 billion CFU once daily) for 4 weeks. Funding came from Juntendo University's Department of Microbiota Research; three authors were from Morinaga, the strain's maker, and are members of that department. (Takeda et al. 2023, Am J Gastroenterol)
80 adults (79 completed, mean age 77.9) diagnosed with chronic constipation in Japan.
The main outcome, the change in total constipation score versus placebo, was not significant (P = 0.074). Stool frequency improved more than on placebo (P = 0.008), and failure of evacuation tended to improve (P = 0.051). Few adverse events related to the probiotic were seen.
Randomized, double-blind, placebo-controlled parallel trial of a daily sachet with 5 billion CFU of BB536 or placebo for 10 months; only the 219 children who fully complied were analyzed; BB536 had no significant effect on diarrhea. Three authors were from Morinaga, the strain's maker. (Lau et al. 2018, Benef Microbes)
520 healthy Malaysian children aged 2 to 6 (219 analyzed).
The mean number of respiratory illnesses over 10 months differed significantly between groups in favor of BB536, and sore throat lasted 46% less long (P = 0.018). Fever, runny nose and cough durations were only marginally shorter (P = 0.084 to 0.087).
Randomized, double-blind, placebo-controlled trial of B. longum BB536 during the cedar pollen season; the first author was from Morinaga, the strain's maker. The pollen-season rise in plasma TARC, a Th2-related chemokine, was smaller on BB536, while cedar-pollen-specific IgE only tended to rise less. (Xiao et al. 2006, Clin Exp Allergy)
44 people with Japanese cedar pollinosis, 13 weeks.
Fewer people on BB536 dropped out early because of severe symptoms or allergy medication (P = 0.0057 vs placebo), and rhinorrhea, nasal blockage and composite symptom scores fell more than on placebo.
Randomized, double-blind, placebo-controlled trial of 1 x 10^9 CFU a day for 8 weeks; registered as NCT04167475 with PrecisionBiotics as sponsor; four co-authors are or were employees of Novonesis or PrecisionBiotics, which own the strain. (Patterson et al. 2024, Sci Rep)
89 adults aged 18 to 45 with impaired sleep quality (PSQI global score 5 or higher).
The primary outcome, PSQI global score, improved in both groups with no difference at 8 weeks. The PSQI sleep quality and daytime dysfunction components improved more on the strain at week 4, and social functioning and energy were better at week 8. Actigraphy sleep measures did not differ.
Randomized, double-blind, placebo-controlled trial of 1 x 10^10 CFU a day for 8 weeks; registered as NCT04925440 with PrecisionBiotics as sponsor; the registry lists people taking antidepressants, anti-anxiety or sleep medicines as excluded; seven of the nine authors are from Novonesis, which owns the strain. (Seamans et al. 2026, Exp Clin Psychopharmacol)
168 adults aged 18 to 70 with mild to moderate depressive symptoms.
The primary outcome, change in Beck Depression Inventory-II score, did not differ from placebo at week 4 or week 8. At week 4, PSQI sleep scores and PHQ-9 depression scores fell more on the strain, and SF-36 vitality, mental health and social functioning were better; only vitality was still better at week 8.
Within-participant study in which everyone took placebo for 4 weeks and then 1 x 10^9 CFU a day of B. longum 1714 for 4 weeks, in fixed order, with tests at baseline and after each phase; run at University College Cork. Results: total salivary cortisol output during the socially evaluated cold pressor test and overall daily perceived stress were lower after the strain than after placebo, while the cortisol rise over the test did not differ by phase; state anxiety rose during the test after placebo but not after the strain. Errors on a visual and spatial memory task fell after both phases compared with the first visit, with no direct strain versus placebo test reported. Alimentary Health supplied the products and its research director was a co-author. (Allen et al. 2016, Transl Psychiatry)
22 healthy men.
The comparison was not randomized: placebo always came first, so time, order and practice effects cannot be ruled out. Frontal midline EEG mobility was higher after the strain phase.
Exploratory randomized, double-blind, placebo-controlled trial. 46 billion CFU per day of BB536 for 4 weeks, with both groups also taking 70 g per day of whey protein. Six of the eight authors are Morinaga employees, and Morinaga made and supplied the products. (Miyamoto et al. 2026, J Int Soc Sports Nutr)
60 healthy male athletes, average age about 18.6 years, all on a high protein diet.
In the overall group there were no significant differences between BB536 and placebo in gastrointestinal outcomes, gut microbiota measures, or metabolite profiles. Diarrhea scores improved from baseline within the BB536 group, and some differences showed up in subgroups defined by starting gut bacteria, but the authors state these should be read as exploratory and hypothesis-generating because they did not extend to the full group. The study also cannot separate BB536 from the whey protein everyone was taking.
Side effects and drug interactions
Common Potential side effects
Important Drug interactions
Frequently asked questions about Bifidobacterium longum
What is Bifidobacterium longum used for?
B. longum is studied for bowel regularity and abdominal comfort, respiratory illnesses and nasal comfort in pollen season, and, as strain 1714, for sleep, mood and the stress response. Results depend on the strain, several trials missed their main goal, and each strain has its own page on this site.
Does B. longum help with stress or mood?
Strain 1714 is the one studied. Its randomized trials did not beat placebo on their main stress or depression scores; some secondary sleep and mood ratings were better than placebo at 4 weeks. A calmer stress response was seen only in a small study where placebo always came first. Choose a product that names the strain studied.
What is the recommended dosage of Bifidobacterium longum?
Doses in trials depend on the strain: about 1 billion CFU a day for 1714 (10 billion in one mood trial), 100 million CFU for 35624 and 5 to 100 billion CFU a day for BB536. Follow the product's label and check that it names the strain.
Is Bifidobacterium longum safe, and does it have side effects?
Few side effects were reported in the trials cited here. NCCIH notes that the risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems, so people in those groups should ask a doctor first.
Does the strain on the label matter?
Yes. Each trial described on this page tested one named strain, and a result for one strain cannot be assumed for another. Strains 1714, BB536, 35624 and R0175 each have their own page on this site. Choose a product that names its strain and check that the strain was tested for the effect you want.
What is Bifidobacterium longum?
Bifidobacterium longum is a probiotic gut bacterium; bifidobacteria often dominate the gut of breastfed infants and make up a much smaller share of the adult gut.
Does Bifidobacterium longum interact with any medications?
Possible interactions include: No interaction studies of these strains are cited on this page; the points below are precautions. Antibiotics: no cited study tested these strains alongside antibiotics; ask a pharmacist about spacing a live probiotic from antibiotic doses. If you take prescription medication, check with a pharmacist or doctor before using it.
How strong is the scientific evidence for Bifidobacterium longum?
NutraSmarts rates the evidence for Bifidobacterium longum as Limited (2 out of 5). It is backed by 9 study summaries and 19 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.
References(19 citations)
Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.
- Bifidobacterium longum BB536 is associated with improvements in gastrointestinal symptoms and odor-related metabolites in microbiota-defined subgroups of male athletes consuming a high-protein diet: exploratory randomized double‑blind placebo‑controlled trial. J Int Soc Sports Nutr. 2026;23(1):2664664. doi: 10.1080/15502783.2026.2664664.PubMedUsed to support: Exploratory randomized trial in 60 male athletes on a high-protein diet given BB536 (46 billion CFU/day) or placebo for 4 weeks. No differences between groups were found in the whole group; diarrhea-related scores improved within the BB536 group, and odor-related metabolites fell only in post hoc subgroups. Six authors are Morinaga employees.
- Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial. Clin Exp Allergy. 2006;36(11):1425-35. doi: 10.1111/j.1365-2222.2006.02575.x.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 44 people with Japanese cedar pollinosis over 13 weeks of the pollen season: fewer early withdrawals for severe symptoms or medication and lower rhinorrhea, nasal blockage and composite symptom scores than placebo; the rise in plasma TARC was suppressed and cedar-specific IgE only tended to rise less. The first author was from Morinaga, the maker of BB536.
- Bifidobacterium longum BB536 alleviated upper respiratory illnesses and modulated gut microbiota profiles in Malaysian pre-school children. Benef Microbes. 2018;9(1):61-70. doi: 10.3920/BM2017.0063.PubMedUsed to support: 10-month randomized, double-blind, placebo-controlled trial in 520 healthy Malaysian children aged 2 to 6 given BB536 (5 billion CFU/day) or placebo. In the 219 fully compliant children analyzed, the BB536 group had fewer respiratory illnesses and a 46% shorter sore throat duration (P = 0.018), with only marginal effects on fever, runny nose and cough and no effect on diarrhea. Three authors were from Morinaga.
- Effects of Bifidobacterium longum BB536 administration on influenza infection, influenza vaccine antibody titer, and cell-mediated immunity in the elderly. Biosci Biotechnol Biochem. 2010;74(5):939-45. doi: 10.1271/bbb.90749.PubMedUsed to support: 27 elderly adults (mean age 86.7) took BB536 (100 billion CFU/day) for 5 weeks, with a flu vaccine at week 3, and were then randomized to BB536 or placebo for 14 weeks. Fewer contracted influenza or had fever on BB536, and NK cell and neutrophil activity only tended to stay higher. Four of the five authors were from Morinaga Milk Industry, the strain maker.
- Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers. Transl Psychiatry. 2016;6(11):e939. doi: 10.1038/tp.2016.191.PubMedUsed to support: Within-participant study in 22 healthy men given placebo and then B. longum 1714 (1 billion CFU a day) for 4 weeks each, in fixed order: total cortisol output in a cold pressor stress test and overall daily stress were lower after the strain than after placebo, though the cortisol rise over the test did not differ by phase; memory errors fell after both phases versus the first visit; frontal EEG mobility rose. Alimentary Health supplied the products and its research director was a co-author.
- Bifidobacterium longum 1714™ Strain Modulates Brain Activity of Healthy Volunteers During Social Stress. Am J Gastroenterol. 2019;114(7):1152-1162. doi: 10.14309/ajg.0000000000000203.PubMedUsed to support: Randomized, double-blind trial in 40 healthy volunteers given B. longum 1714 or placebo for 4 weeks. The strain changed resting and stress-related brain activity on MEG, linked to vitality, but felt social stress rose in both groups with no behavioral difference. Alimentary Health supplied the products, its technical director was a co-author and the senior author consults for it; EU research funding.
- Improvements in sleep indices during exam stress due to consumption of a Bifidobacterium longum. Brain Behav Immun Health. 2021;10:100174. doi: 10.1016/j.bbih.2020.100174.PubMedUsed to support: Double-blind randomized placebo-controlled crossover study in 20 male students during exams (1 x 10^9 CFU a day): the primary outcome, self-reported stress, did not differ; sleep quality and duration were better on B. longum 1714 after adjusting for baseline; no effect on depression or any cognitive test. Funded by Science Foundation Ireland and the EU.
- Bifidobacterium longum 1714 improves sleep quality and aspects of well-being in healthy adults: a randomized, double-blind, placebo-controlled clinical trial. Sci Rep. 2024;14(1):3725. doi: 10.1038/s41598-024-53810-w.PubMedUsed to support: In 89 adults with poor sleep, 8 weeks of B. longum 1714 (1 billion CFU/day) did not beat placebo on the main sleep score; the sleep quality component and daytime sleepiness improved faster at 4 weeks, and energy and social functioning were better at 8 weeks. Actigraphy did not change. Four authors are or were employees of Novonesis or PrecisionBiotics, which own the strain.
- Effects of Bifidobacterium longum 1714 on low mood and related symptoms: A randomized, double-blind, placebo-controlled trial. Exp Clin Psychopharmacol. 2026;34(4):341-351. doi: 10.1037/pha0000839.PubMedUsed to support: In 168 adults with mild to moderate depression, 8 weeks of B. longum 1714 (10 billion CFU a day) did not beat placebo on the main depression score; sleep and secondary mood scores were better at week 4 but not week 8, and vitality stayed better at week 8. Seven of the nine authors are from Novonesis.
- Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581-90. doi: 10.1111/j.1572-0241.2006.00734.x.PubMedUsed to support: In 362 women with IBS, 4 weeks of B. infantis 35624 capsules at 100 million CFU (the abstract gives the units as cfu/mL) beat placebo on abdominal pain or discomfort, the primary outcome, and on bloating, bowel dysfunction and global relief; the 1 million and 10 billion CFU doses did not differ from placebo, and the 10 billion dose had formulation problems.
- Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating. Am J Gastroenterol. 2017;112(1):145-151. doi: 10.1038/ajg.2016.511.PubMedUsed to support: In 302 adults with frequent abdominal discomfort and bloating who were not under medical care, 4 weeks of B. infantis 35624 (1 billion CFU/day) did not reduce symptom severity more than placebo; bloating-free days were more frequent on the probiotic.
- Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191-1197. doi: 10.1080/03007995.2017.1292230.PubMedUsed to support: Pooled analysis of five randomized trials, three of strain 35624 on its own and two of multi-strain products containing it. Across the three single-strain trials there was no significant improvement in abdominal pain, bloating or bowel habit satisfaction; benefit appeared only with the multi-strain products. The authors conclude that the efficacy of the strain on its own has not been confirmed.
- Genome Analysis and Characterisation of the Exopolysaccharide Produced by Bifidobacterium longum subsp. longum 35624™. PLoS One. 2016;11(9):e0162983. doi: 10.1371/journal.pone.0162983.PubMedUsed to support: Genome sequencing showed that strain 35624, formerly named B. longum subsp. infantis, belongs to subspecies longum.
- Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial. Am J Gastroenterol. 2023;118(3):561-568. doi: 10.14309/ajg.0000000000002028.PubMedUsed to support: In 80 older adults with chronic constipation, 4 weeks of BB536 (50 billion CFU/day) did not beat placebo on the main constipation score (P = 0.074), but stool frequency improved more than on placebo (P = 0.008). Registered as UMIN 000033031; funded by Juntendo University's Department of Microbiota Research; three authors were from Morinaga.
- The genome sequence of Bifidobacterium longum subsp. infantis reveals adaptations for milk utilization within the infant microbiome. Proc Natl Acad Sci U S A. 2008;105(48):18964-9. doi: 10.1073/pnas.0809584105.PubMedUsed to support: Genome study showing that B. longum subsp. infantis carries a 43 kbp gene cluster for using human milk oligosaccharides, and that the breastfed infant gut is often dominated by bifidobacteria.
- Bifidobacteria and Butyrate-Producing Colon Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. Front Microbiol. 2016;7:979. doi: 10.3389/fmicb.2016.00979.PubMedUsed to support: Review describing cross-feeding between bifidobacteria and butyrate-producing colon bacteria, butyrate as the main energy source for colon cells, and the drop in bifidobacteria from up to 90% of the colon microbiota in breastfed infants to under 5% in adults.
- The Effects of Bifidobacterium Longum 1714® in a Population With Low Mood ClinicalTrials.gov (not PubMed-indexed). 2021;NCT04925440. First posted June 14, 2021; last updated November 10, 2022; accessed 2026..SourceUsed to support: Not PubMed-indexed. Trial registration for the 8-week low-mood trial: sponsored by PrecisionBiotics Group Ltd., 168 enrolled, adults meeting criteria for major depression with mild to moderate scores; people taking antidepressants, anti-anxiety medicines, antipsychotics, hypnotics or prescribed sleep medicines were excluded. Primary outcome: change in BDI-II score.
- Probiotics: Usefulness and Safety NCCIH (not PubMed-indexed). 2019;Web page, last updated August 2019, accessed 2026..SourceUsed to support: Not PubMed-indexed. US government consumer page: the risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems, and severe or fatal infections have been reported in premature infants given probiotics.
- Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome ClinicalTrials.gov (not PubMed-indexed). 2005;NCT00135031. First posted August 25, 2005; last updated June 15, 2011; accessed 2026..SourceUsed to support: Not PubMed-indexed. Registry entry for the 362-person capsule trial of strain 35624: Procter and Gamble is listed as lead sponsor and Alimentary Health Ltd as collaborator, and the primary efficacy variable was the abdominal pain score.